Table 3.

Multivariate adjusted weight loss and survival by stage and baseline BMI: diagnosis to follow-up

# EventsLarge loss (≥10%)Modest loss (5%–9.9%)Stable (−4.9%–4.9%)P LossPinteraction
Colorectal cancer–specific mortality
 Stage I (N = 797)246.76 (1.93–23.6)1.63 (0.44–6.02)Referent0.03
 Stage II (N = 894)722.42 (1.19–4.93)1.48 (0.72–3.07)Referent0.01
 Stage III (N = 1,090)2153.44 (2.37–5.00)1.59 (1.05–2.41)Referent<0.00010.95
 BMI 18.5–24.9 kg/m2 (N = 835)933.22 (1.67–6.23)1.46 (0.77–2.78)Referent0.01
 BMI 25–29.9 kg/m2 (N = 1,014)1063.72 (2.17–6.39)1.66 (0.91–3.00)Referent<0.0001
 BMI ≥30 kg/m2 (N = 889)1032.68 (1.62–4.43)1.30 (0.68–2.51)Referent<0.00010.96
 Chemotherapy (N = 1,315)2193.02 (2.10–4.35)1.28 (0.83–1.97)Referent<0.0001
 No chemotherapy (N = 1,447)884.07 (2.14–7.74)2.44 (1.35–4.43)Referent0.00010.19
 Age <63 years (N = 1,392)1543.76 (2.39–5.92)1.41 (0.82–2.42)Referent<0.0001
 Age ≥63 years (N = 1,389)1572.94 (1.89–4.58)1.74 (1.10–2.74)Referent<0.00010.63
 Men (N = 1,380)1543.54 (2.19–5.73)1.33 (0.78–2.26)Referent<0.00010.45
 Women (N = 1,401)1572.96 (1.93–4.52)1.81 (1.14–2.87)Referent<0.0001
 Colon (N = 1,969)2083.67 (2.48–5.45)1.33 (0.84–2.11)Referent<0.00010.21
 Rectal (N = 812)1032.98 (1.75–5.06)2.17 (1.26–3.76)Referent<0.0001
 Smoking-never (N = 1,307)1292.31 (1.33–4.00)1.55 (0.94–2.58)Referent0.0030.55
 Smoking-former (N = 1,149)1383.87 (2.45–6.13)1.84 (1.10–3.07)Referent<0.0001
 Smoking-current (N = 322)445.21 (2.08–13.02)0.72 (0.16–3.31)Referent0.003
 No significant comorbidities (N = 1,941)1962.94 (1.97–4.38)1.47 (0.94–2.28)Referent<0.00010.89
 Significant comorbidities at diagnosis (N = 840)1153.76 (2.23–6.34)1.80 (1.02–3.17)Referent<0.0001
Overall mortality
 Stage I (N = 797)876.01 (3.16–11.4)2.34 (1.23–4.46)Referent<0.0001
 Stage II (N = 894)1682.17 (1.34–3.51)1.36 (0.83–2.23)Referent0.0001
 Stage III (N = 1,090)2943.50 (2.52–4.85)1.80 (1.27–2.55)Referent<0.00010.48
 BMI 18.5–24.9 kg/m2 (N = 835)1644.20 (2.58–6.85)1.50 (0.91–2.48)Referent<0.0001
 BMI 25–29.9 kg/m2 (N = 1,014)1933.17 (2.07–4.84)2.22 (1.47–3.35)Referent<0.0001
 BMI ≥ 30 kg/m2 (N = 889)1762.83 (1.91–4.20)1.31 (0.80–2.15)Referent<0.00010.69
 Chemotherapy (N = 1,315)2963.05 (2.22–4.17)1.36 (0.94–1.96)Referent<0.0001
 No chemotherapy (N = 1,447)2473.72 (2.51–5.52)2.27 (1.57–3.27)Referent<0.00010.09
 Age <63 years (N = 1,392)2124.14 (2.83–6.04)1.21 (0.74–1.98)Referent<0.0001
 Age ≥63 years (N = 1,389)3372.98 (2.16–4.16)2.12 (1.56–2.88)Referent<0.00010.03
 Men (N = 1,380)2853.40 (2.35–4.91)1.84 (1.27–2.65)Referent<0.00010.85
 Women (N = 1,401)2642.98 (2.13–4.16)1.54 (1.07–2.21)Referent<0.0001
 Colon (N = 1,969)3893.76 (2.79–5.07)1.58 (1.14–2.19)Referent<0.00010.12
 Rectal (N = 812)1602.64 (1.71–4.08)2.12 (1.37–3.28)Referent<0.0001
 Smoking-never (N = 1307)1992.23 (1.39–3.59)1.55 (1.03–2.34)Referent0.00010.41
 Smoking-former (N = 1,149)2643.80 (2.69–5.38)2.07 (1.44–2.98)Referent<0.0001
 Smoking-current (N = 322)856.12 (3.16–11.83)1.30 (0.51–3.29)Referent<0.0001
 No significant comorbidities (N = 1,941)2982.68 (1.90–3.78)1.42 (0.98–2.05)Referent<0.00010.43
 Significant comorbidities at diagnosis (N = 840)2513.90 (2.73–5.57)2.04 (1.41–2.94)Referent<0.0001
  • NOTE: Adjusted for age and weight at diagnosis (continuous), gender (female versus male), race/ethnicity (black, Hispanic, or Asian versus non-Hispanic white), stage (II or III versus I), grade (moderate or poorly/undifferentiated versus well differentiated), chemotherapy (not received versus received), radiotherapy (not received versus received), and cancer site (colon versus rectal).